Xtandi 80 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FCMQR
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,170
Award facts
- Contract value 100% obligated
- $4,169.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a $4,169.59 firm fixed-price delivery order from the Defense Logistics Agency on April 29, 2025, for 60 tablets of Xtandi 80 mg. This award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at approximately $500 million and valid through November 2026. The contract carries no set-aside designation, allowing the company to compete directly in the federal procurement market. Xtandi is an oncology medication used in prostate cancer treatment, reflecting the company's specialization in supplying prescription medications and medical supplies to military and federal healthcare facilities nationwide.
The delivery order will be fulfilled from the contractor's location in Park Ridge, Illinois, with a completion date of April 30, 2025. As the prime contractor on this delivery order, DMS Pharmaceutical Group leverages its established position within the Defense Logistics Agency's pharmaceutical supply chain to provide direct distribution of specialty medications to Department of Defense healthcare sites. The company's contract portfolio demonstrates consistent success in securing pharmaceutical delivery orders across a broad range of medical products, from contraceptive devices to oncology treatments and biologics, establishing it as a critical supplier within the federal pharmaceutical distribution network.
Quick answers
Who was awarded contract SPE2DB25FCMQR?
SPE2DB25FCMQR was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on April 29, 2025.
How much is contract SPE2DB25FCMQR worth?
The government has obligated $4,170 on SPE2DB25FCMQR.
Is contract SPE2DB25FCMQR an order under another contract?
Yes. SPE2DB25FCMQR is a delivery order under SPE2DB24D9144, an indefinite delivery contract.
Was contract SPE2DB25FCMQR competed?
The extent of competition for SPE2DB25FCMQR was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award